Valneva (NASDAQ:VALN) SE (NASDAQ: VALN) is a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical needs. Headquartered in Saint-Herblain, France, and Solna, Sweden, Valneva operates a fully integrated business model that spans research, clinical development, and commercial supply. The company’s strategy centers on leveraging its expertise in vaccine design and scalable manufacturing to address diseases that pose serious threats to global public health.
Valneva’s commercial product portfolio includes a range of approved vaccines. Ixiaro®/JESPECT® is an inactivated vaccine for the prevention of Japanese encephalitis in adults and children, and Dukoral® is an oral vaccine for cholera and prevention of traveler’s diarrhea caused by enterotoxigenic Escherichia coli (ETEC). In addition to these established products, Valneva brought to market VLA2001, a fully inactivated, adjuvanted SARS-CoV-2 vaccine authorized in multiple countries for primary vaccination against COVID-19. These offerings are supported by Valneva’s global manufacturing facilities in Scotland, Sweden, France and the United States.
The company’s pipeline is built around three late-stage vaccine candidates: VLA1553, a single-dose chikungunya vaccine; VLA15, a multivalent Lyme disease vaccine; and VLA2002, a next-generation Japanese encephalitis vaccine. Valneva has completed Phase 3 trials for chikungunya and is conducting global pivotal studies for Lyme disease, collaborating with public health agencies and research institutions to support licensure. Valneva’s R&D efforts also investigate vaccines for Zika and other emerging pathogens, reflecting a commitment to proactive responses against potential outbreaks.
Valneva was formed through the merger of Intercell AG and Vivalis SA in 2013, combining decades of innovation in vaccine science. The company is led by Chief Executive Officer Thomas Lingelbach, who brings more than 25 years of experience in biotech and vaccines, and Chief Medical Officer Dr. Catherine Yen, an expert in clinical development. Valneva serves public and private sector customers across Europe, North America, the Asia-Pacific region and other global markets, partnering with governments, international health organizations and commercial distributors to enhance vaccine access worldwide.
